“Patients With Moderate-to-Severe Atopic Dermatitis Maintained Depth of Response Up to 2 Years With Continuous Abrocitinib Treatment”. SKIN The Journal of Cutaneous Medicine 9, no. 6 (November 10, 2025): s617. Accessed April 29, 2026. https://skin.dermsquared.com/skin/article/view/3821.